PubMed Health⌕ Search

Biomedical subjects

C Sturgeon

Publications and source records attributed to C Sturgeon.

6 recordsLinked to original sources
PubMed1995

A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery.

BACKGROUND: Approximately 70% of patients who are going to develop tumor recurrence following curative colorectal surgery do so within 24 months of surgery. PATIENTS AND METHODS: The relationship was prospectively examined between an ongoing acute-phase response and subsequent clinical relapse in 36 colorectal cancer patients who had undergone a curative resection. Approximately 4 months after their operation, patients were grouped according to the presence (n = 15) or absence (n = 21) of an acute-phase response (C-reactive protein > 5 mg/L) and were followed-up for a minimum of 24 months. RESULTS: Age, tumor site, and serum carcinoembryonic antigen concentrations were similar in both groups. There was a significantly higher recurrence rate in patients with an acute-phase response (11 of 15) compared to those with no acute-phase response (2 of 21, P < 0.01). CONCLUSIONS: These results are consistent with the presence of an acute-phase response being an important predictive factor in the early stages of tumor recurrence in patients who have had apparently curative colorectal surgery.

Acute-Phase Reaction↗
PubMed1995

Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients.

The regulation of acute phase protein production and the relationship of the acute phase protein response to tumour growth was examined in colorectal cancer patients (n = 9). Ibuprofen (1200 mg/d) was administered for 8-11 days. Following ibuprofen administration there were reductions in circulating concentrations of C-reactive protein (P = 0.01), interleukin-6 (P = 0.06), cortisol (P = 0.04) and also in the platelet count (P = 0.01). There was no significant change in albumin, insulin and carcinoembryonic antigen. These results indicate that ibuprofen administered over a prolonged period substantially reduces acute protein production via its effect on interleukin-6 and cortisol. It remains to be determined whether ibuprofen is useful in moderating tumour growth in colorectal cancer patients.

Acute-Phase Proteins↗
PubMed1995

Raised carcinoembryonic antigen level as an indicator of recurrent disease in follow up of patients with colorectal cancer.

BACKGROUND: Serum carcinoembryonic antigen level is raised in 80% of patients undergoing colonic resection for cancer. Subsequent elevation in the follow-up period may precede signs and symptoms as an indicator of recurrent disease. there is little evidence that "classical" follow up of patients in the general surgical outpatient clinic improves either survival or quality of life. Regular carcinoembryonic antigen level estimation requested by the general practitioner, allied to day-case colonoscopic surveillance may be a more rational approach. AIM: A study was undertaken to investigate the relationship between raised carcinoembryonic antigen level and the recurrence of colorectal cancer in patients following a curative primary resection. METHOD: Retrospective analysis was carried out on the notes of 125 patients who had attended a dedicated hospital colorectal follow-up clinic between 1988 and 1992. Carcinoembryonic antigen level data were obtained by subsequent examination of the University of Edinburgh Department of Clinical Chemistry (immunoassay section) carcinoembryonic antigen database. RESULTS: A single carcinoembryonic level result of more than 100 ul-1 (normal range less than 60 ul-1) was found to be a highly sensitive (87%), specific (89%), and accurate (88%) indicator of recurrent disease. Raised carcinoembryonic antigen level preceded symptoms in 72% of patients with recurrence of colorectal cancer. CONCLUSION: Sequential laboratory estimation of carcinoembryonic antigen level organized by the general practitioner may represent an accurate method of detecting recurrent colorectal disease. Hospital review could be limited to colonoscopic surveillance and restaging of patients referred with evidence of recurrent disease.

Adult↗
PubMed1987

Symptomatic atlantoaxial dislocation in Down's syndrome.

Four patients with Down's syndrome suffered compression of the spinal cord secondary to atlantoaxial dislocation. All four developed inability to walk and quadriparesis, with signs of cervical myelopathy. It is important to recognize this potentially fatal complication of the syndrome. Immediate immobilization of the neck, followed by cervical roentgenograms, should be done in any patient with Down's syndrome who presents with neck pain, torticollis, urinary incontinence, or loss of ambulation. Surgical repair with fusion of the first and second cervical vertebrae can be carried out later.

Adolescent↗
PubMedDate not supplied

Serological monitoring of epithelial ovarian cancer.

Serum CA125 measurement has an established role in monitoring epithelial ovarian cancer patients, assisting in determining response to chemotherapy and providing a lead time to clinical relapse. Over the past few years there has been a decrease in the use of second-look laparotomy to determine response; however, this is largely due to the lack of impact that this procedure has on survival rather than the growing use of less invasive scanning techniques or CA 125 assay to determine disease status. The value of a marker lead time depends ultimately on a patient's remaining therapeutic options; the influence on survival of therapeutic intervention at pre-clinical diagnosis of relapse remains to be tested in a randomized controlled trial. The third area where CA 125 may help patient management is in predicting progression-free survival and overall survival. Treating patients with aggressive chemotherapy regimes would not be justified (given the deterioration in the quality of life for a period of months that may result from such therapy) if a poor outcome could be predicted. Deciding when to stop ineffective treatment is extremely difficult for the clinician given patients' desire for active therapy. The prognostic value of CA 125 needs to be further clarified before it can influence such treatment decisions. The aim of this study was to help clarify the role of CA 125 in patient management and to assess several other putative EOC markers, including determinants found on the polymorphic epithelial mucin (PEM)--the most promising alternative marker protein to date.

Antibodies, Monoclonal↗